NEW YORK, May 15, 2017 /PRNewswire/ --
Featured on Stock-Callers.com today are these four major players in the DrugManufacturers space: Alliqua BioMedical Inc. (NASDAQ: ALQA), AbbVie Inc. (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Merck & Co. Inc. (NYSE: MRK). The Pharmaceutical industry consists of companies that research, develop, market, and distribute
Yardley, Pennsylvania-based Alliqua BioMedical Inc.'s stock finished last Friday's session 2.61% lower at $0.37 with a total trading volume of 55,724 shares. The Company's shares are trading below their 50-day moving average by 27.87%. Shares of the Company, which commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue, have a Relative Strength Index (RSI) of 36.67.
On May 09th, 2017, Alliqua BioMedical announced financial results for Q1 ended March 31st, 2017. Total revenue from continuing operations increased 16% year-over-year to $4.6 million; product revenue from continuing operations increased 28% year-over-year to $4.4 million; gross margin was 64% for Q1 2017, compared to 60% in the same period last year; and adjusted EBITDA loss decreased by $1.8 million, or 36% year-over-year, to ($3.2) million. Visit us today and download your complete report on ALQA for free at:
On Friday, shares in North Chicago, Illinois-based AbbVie Inc. ended the session 1.16% higher at $66.06. The stock recorded a trading volume of 6.06 million shares, which was higher than its three months average volume of 6.03 million shares. The Company's shares have gained 2.63% in the last one month, 10.42% in the previous three months, and 7.62% on an YTD basis. The stock is trading 1.84% above its 50-day moving average and 6.41% above its 200-day moving average. Moreover, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 54.02.
On May 05th, 2017, AbbVie announced that it will participate in the UBS Global Healthcare Conference on Monday, May 22nd, 2017. Richard A. Gonzalez, Chairman of the board and CEO, will present at 7:00 a.m. CT. A live audio webcast of the presentation will be accessible on the Company's Investor Relations website. The complimentary research report on ABBV can be accessed at:
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's shares gained 0.36%, closing the session at $123.64 with a total trading volume of 4.10 million shares. The stock has gained 8.00% over the previous three months and 8.03% on an YTD basis. Shares of the Company are trading 4.70% above their 200-day moving average. Additionally, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 45.75.
On May 11th, 2017, Johnson & Johnson announced that it will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 08th, 2017, at the Grand Hyatt New York. Alex Gorsky, Chairman and CEO, will represent the Company in a session scheduled at 10:00 a.m. ET. This webcast will be available on the Company's website. Register for free on Stock-Callers.com and download the PDF research report on JNJ at:
Last Friday at the close, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 10.30 million shares, which was above their three months average volume of 9.19 million shares. The stock ended the session 1.33% lower at $63.57. The Company's shares have advanced 0.82% in the past month and 8.76% since the start of this year. The stock is trading above its 200-day moving average by 2.86%. Furthermore, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 51.75.
On May 10th, 2017, Merck announced that the US FDA has approved KEYTRUDA® (pembrolizumab), the Company's anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta®) and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. Under the FDA's accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival. Get free access to your research report on MRK at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All